Anti-HIV Effects of Chloroquine: Inhibition of Viral Particle Glycosylation and Synergism with Protease Inhibitors

Journal of Acquired Immune Deficiency Syndromes

Volumn 35, Issue 3, 2004, Pages 223-232

  Savarino, Andrea ^a,b   Lucia, Mothanje B ^a   Rastrelli, Elena ^a   Rutella, Sergio ^a   Golotta, Caterina ^a   Morra, Emanuella ^c   Tamburrini, Enrica ^a   Perno, Carlo Federico ^d   Boelaert, Johan R ^e   Sperber, Kirk ^a   Cauda, Roberto ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY OF TURIN   (Italy)

^d UNIVERSITY OF ROME TOR VERGATA   (Italy)

^e AZ Sint Jan   (Belgium)

Author keywords

Antimalarial; Developing countries; Multidrug resistance protein 1; P glycoprotein; Protease inhibitors; Synergism

Indexed keywords

CARBOXYFLUORESCEIN; CHLOROQUINE; GLUCOSAMINE; GLYCOPROTEIN P; INDINAVIR; MULTIDRUG RESISTANCE PROTEIN 1; PROTEINASE INHIBITOR; RHODAMINE 123; RITONAVIR; SAQUINAVIR; ZIDOVUDINE;

ANTIVIRAL ACTIVITY; ARTICLE; DRUG EFFECT; DRUG INHIBITION; DRUG MECHANISM; DRUG POTENTIATION; ENZYME LINKED IMMUNOSORBENT ASSAY; GLYCOSYLATION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS; MALARIA CONTROL; NONHUMAN; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEINASE INHIBITION; T LYMPHOCYTE; VIRUS PARTICLE; VIRUS REPLICATION;

ANTI-HIV AGENTS; APOPTOSIS; CELL DIVISION; CELL LINE; CELL SURVIVAL; CHLOROQUINE; CYSTEINE; DRUG SYNERGISM; GLYCOSYLATION; HIV PROTEASE INHIBITORS; HIV-1; HUMANS; INDINAVIR; METHIONINE; VIRUS REPLICATION; ZIDOVUDINE;

EID: 10744225033     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/00126334-200403010-00002     Document Type: Article

References (40)

1. Tsai WP, Nara PL, Kung HF, et al. Inhibition of human immunodeficiency virus infectivity by chloroquine. AIDS Res Hum Retroviruses. 1990;6:481-489.
2. Savarino A, Gennero L, Chen HC, et al. Anti-HIV effects of chloroquine: mechanisms of inhibition and spectrum of activity. AIDS. 2001;15:2221-2229.
3. Savarino A, Gennero L, Boelaert JR, et al. The anti-HIV-1 activity of chloroquine. J Clin Virol. 2001;20:131-135.
4. Sperber K, Louie M, Kraus T, et al. Hydroxychloroquine treatment of patients with human immunodeficiency virus type 1. Clin Ther. 1995;17:622-636.
5. Paton NI, Aboulhab J, Karim F. Hydroxychloroquine, hydroxycarbamide, and didanosine as economic treatment for HIV-1 [letter]. Lancet. 2002;359:1667-1668.
6. Chiang G, Sassaroli M, Louie M, et al. Inhibition of HIV-1 replication by hydroxychloroquine: mechanism of action and comparison with zidovudine. Clin Ther. 1996;18:1080-1092.
7. Sperber K, Chiang G, Chen H, et al. Comparison of hydroxychloroquine with zidovudine in asymptomatic patients infected with HIV-1. Clin Ther. 1997;19:913-923.
8. Boelaert JR, Sperber K, Piette J. Chloroquine exerts an additive in vitro anti-HIV type 1 effect when associated with didanosine and hydroxyurea. AIDS Res Hum Retroviruses. 1999;15:1241-1247.
9. Boelaert JR, Sperber K, Piette J. Chloroquine exerts an additive in vitro anti-HIV-1 effect, when combined to zidovudine and hydroxyurea. Biochem Pharmacol. 2001;61:1531-1535.
10. Weller IV, Williams IG. ABC of AIDS. Antiretroviral drugs. BMJ. 2001; 322:1410-1412.
11. Lee CG, Gottesman MM, Cardarelli CO, et al. HIV-1 protease inhibitors are substrates for the MDR1 multidrug transporter. Biochemistry (Mosc). 1998;37:3594-3601.
12. Kim RB, Fromm MF, Wandel C, et al. The drug transporter P-glycoprotein limits oral absorption and brain entry of HIV-1 protease inhibitors. J Clin Invest. 1998;101:289-294.
13. Washington CB, Wiltshire HR, Man M, et al. The deposition of saquinavir in normal and P-glycoprotein deficient mice, rats, and in cultured cells. Drug Metab Dispos. 2000;28:1058-1062.
14. van der Sandt ICJ, Vos CMO, Nabulsi L, et al. Assessment of active transport of HIV protease inhibitors in various cell lines and the in vitro blood-brain barrier. AIDS. 2001;15:483-491.
15. Tiberghien F, Loor F. Ranking of P-glycoprotein substrates and inhibitors by a calcein-AM fluorometry screening assay. Anticancer Drugs. 1996;7:568-578.
16. Vezmar M, Georges E. Reversal of MRP-mediated doxorubicin resistance with quinoline-based drugs. Biochem Pharmacol. 2000;59:1245-1252.
17. Vezmar M, Georges E. Direct binding of chloroquine to the multidrug resistance protein (MRP): possible role for MRP in chloroquine drug transport and resistance in tumor cells. Biochem Pharmacol. 1998;56:733-742.
18. Savarino A, Bensi T, Chiocchetti A, et al. Human CD38 interferes with HIV-1 fusion through a sequence homologous to the V3 loop of the viral envelope glycoprotein gp120. FASEB J. 2003;17:461-463.
19. Debiaggi M, Bruno R, Sacchi P, et al. Antiviral activity of chloroquine against HIV-1 strains resistant to antiretroviral drugs. Antiviral Res. (in press)
20. Jacobsen H, Yasargil K, Winslow DL, et al. Characterization of human immunodeficiency virus mutants with decreased sensitivity to proteinase inhibitor Ro 31-8959. Virology. 1995;206:527-534.
21. Larder BA, Darby G, Richman DD, et al. HIV with reduced sensitivity to zidovudine (AZT) isolated during prolonged therapy. Science. 1989;243: 1731-1734.
22. Perno CF, Cozzi-Lepri A, Balotta C, et al. Secondary mutations in the protease region of human immunodeficiency virus and virologic failure in drug-naive patients treated with protease inhibitor-based therapy. J Infect Dis. 2001;184:983-991.
23. Pugliese A, Comito G, Cantamessa C, et al. Comparison of different in-vitro tests for evaluating immune reactivity. Cell Biochem Funct. 1996;14:63-68.
24. Savarino A, Calosso L, Piragino A, et al. Modulation of surface transferrin receptors in lymphoid cells de novo infected with human immunodeficiency virus type 1. Cell Biochem Funct. 1999;17:47-55.
25. Chen H, Yip YK, George I, et al. Chronically HIV-1 infected monocytic cells induce apoptosis in co-cultured T cells. J Immunol. 1998;161:4257-4267.
26. Sperber K, Ogata S, Sylvester C, et al. A novel macrophage-derived intestinal mucin secretagogue: implications for the pathogenesis of inflammatory bowel disease. Gastroenterology. 1993;104:1302-1309.
27. Lucia MB, Rutella S, Leone G, et al. HIV-Protease inhibitors contribute to P-glycoprotein efflux function defect in peripheral blood lymphocytes from HIV-positive patients receiving HAART. J Acquir Immune Defic Syndr. 2001;27:321-330.
28. van der Kolk DM, de Vries GE, Koning JA, et al. Activity and expression of the multidrug resistance proteins MRP1 and MRP2 in acute myeloid leukemia cells, tumor cell lines, and normal hematopoietic CD34+ peripheral blood cells. Clin Cancer Res. 1998;14:1727-1736.
29. Laupeze B, Amiout L, Courtois L, et al. Use of the anionic dye carboxy-2′-dichlorofluorescein for sensitive flow cytometric detection of multidrug resistance-associated protein activity. Int J Oncol. 1999;15:571-576.
30. Pec MK, Aguirre A, Fernandez JJ, et al. Dehydrothyrsiferol does not modulate multidrug resistance associated protein 1 resistance: a functional screening system for MRP1 substrates. Int J Mol Med. 2002;10:605-608.
31. Ducharme J, Farinotti R. Clinical pharmacokinetics and metabolism of chloroquine. Focus on recent advancements. Clin Pharmacokinet. 1996; 31:257-274.
32. Savarino A, Boelaert JR, Cassone A, et al. Effects of chloroquine on viral infections: an old drug against today's diseases? Lancet Infect Dis. 2003;3:722-727.
33. Trkola A, Purtscher M, Muster T, et al. Human monoclonal antibody 2G12 defines a distinctive neutralization epitope on the gp120 glycoprotein of human immunodeficiency virus type 1. J Virol. 1996;70:1100-1108.
34. Thorens B, Vassalli P. Chloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion. Nature. 1986;321:618-620.
35. Nagy K, Young M, Baboonian C, et al. Antiviral activity of human immunodeficiency virus type 1 protease inhibitors in a single cycle of infection: evidence for a role of protease in the early phase. J Virol. 1994;68:757-765.
36. Speck RR, Yu XF, Hildreth J, et al. Differential effects of P-glycoprotein and multidrug resistance protein-1 on productive human immunodeficiency virus infection. J Infect Dis. 2002;186:332-340.
37. Mechetner EB, Scott B, Moise BS, et al. P-glycoprotein function involves conformational transitions detectable by differential immunoreactivity. Proc Natl Acad Sci USA. 1997;94:12908-12913.
38. Manciu L, Chang XB, Riardan JR, et al. Multidrug resistance protein MRP1 reconstituted into lipid vesicles: secondary structure and nucleotide-induced tertiary structure changes. Biochemistry (Mosc). 2000;39:13026-13033.
39. Kim H, Barroso M, Samanta R, et al. Experimentally induced changes in the endocytic traffic of P-glycoprotein alter drug resistance of cancer cells. Am J Physiol. 1997;273:C687-C702.
40. Boelaert JR, Yaro S, Augustijns P, et al. Chloroquine accumulates in breast-milk cells: potential impact in the prophylaxis of postnatal mother-to-child transmission of HIV-1 [letter]. AIDS. 2001;15:2205-2207.